Použití regorafenibu a SBRT při léčbě plicních metastáz kolorektálního karcinomu


Klin Onkol 2019; 32(5): 388-389. DOI: 10.14735/amko2019388.

Colorectal cancer is the third most common cancer in humans. Metastases are the main cause of death in colorectal cancer patients. The most common areas of metastases include liver, lungs and peritoneum. Lung metastasis will develop in approximately 2–54% of patients with colorectal cancer during the course of the disease. When left untreated, prognosis is poor in metastatic cases with median survival time of 5–9 months [1–3].


Plný text v PDF